Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The effect of dapagliflozin on blood pressure was evaluated in non-hypertensive (<140 mm Hg) and hypertensive (⩾140 mm Hg) patients with type 2 diabetes mellitus. Data were pooled from 13 placebo-controlled studies. Patients received dapagliflozin 10 mg/day ( n = 2360) or placebo ( n = 2295) for up to 24 weeks. Dapagliflozin was associated with placebo-subtracted changes from baseline in systolic and diastolic blood pressures of −3.6 and −1.2 mm Hg, respectively, in hypertensive patients and −2.6 and −1.2 mm Hg, respectively, in non-hypertensive patients. At 24 weeks, a similar proportion of patients experienced measured orthostatic reactions with dapagliflozin versus placebo in hypertensive (6.1% and 6.6%, respectively) and non-hypertensive (4.0% and 4.2%) patients. No clinically relevant difference was observed between dapagliflozin and placebo in heart rate. In conclusion, dapagliflozin 10 mg induces a modest reduction in blood pressure compared with placebo in patients with diabetes with a low risk of orthostatic reactions, regardless of baseline blood pressure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar findings have been reported in short-term trials of other SGLT2 inhibitors, 6,18,19 and the longer-term BP lowering effects of SGLT2 inhibitors in individuals with T2DM and relatively preserved kidney function have been demonstrated in large cardiovascular outcome trials.5,20,21”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [19]
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Levesque, R. J. R. (2017) · Encyclopedia of Adolescence · doi:10.1007/978-3-319-32132-5_447-2 · Cited by 4,021
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Diabetes, Hypertension, and Cardiovascular Disease: An Update
Sowers, J. R., Epstein, M., & Frohlich, E. D. (2001) · Hypertension · doi:10.1161/01.hyp.37.4.1053 · Cited by 1,332
Research works printed but not linked: 2
- Sjostrom CD, 2013, Diabetolgia, 56, S81
- Dornfeld LP, 1985, Int J Obes, 9, 381
Cited by
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Weber, M. A., Mansfield, T. A., Cain, V. A., Iqbal, N., Parikh, S., & Ptaszynska, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00417-9 · Cited by 254
Self-citationHeerspink, H. J. L., Johnsson, E., Gause‐Nilsson, I., Cain, V. A., & Sjöström, C. D. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12654 · Cited by 191
Self-citationAn update on the safety of SGLT2 inhibitors
Scheen, A. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602116 · Cited by 174
Metadata
- Authors
- Sjöström, C. D., Johansson, P., Ptaszynska, A., List, J., & Johnsson, E.
- Affiliations
- AstraZeneca (Sweden) (SE)
- Bristol-Myers Squibb (United States) (US)
- ORCID
- Sjöström, C David
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2015-05-25
- Volume
- 12
- Issue
- 5
- Pages
- 352-358
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- OpenAlex
- W2154525074
- Cited by
- 97
- References
- 25
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 10 · 2023: 6 · 2022: 13 · 2021: 12 · 2020: 9 · 2019: 12 · 2018: 5 · 2017: 7 · 2016: 11 · 2015: 5
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Diabetes and Vascular Disease Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- dapagliflozin, blood pressure reduction, hypertension, type 2 diabetes, SGLT2 inhibitors, orthostatic reaction, heart rate, antihypertensive effect
- MeSH terms
- Adult, Aged, Aged, 80 and over, Benzhydryl Compounds, Blood Pressure, Blood Pressure Determination, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. https://app.cochat.ai/papers/10.1177/1479164115585298
- The paper
- Sjöström, C. D., Johansson, P., Ptaszynska, A., List, J., & Johnsson, E. (2015). Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diabetes and Vascular Disease Research. https://doi.org/10.1177/1479164115585298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.